Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
A registry study is to evaluate the overall survival, use of subsequent anti-cancer therapy, and the long-term safety of subjects who have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type. Follow-Up will occur every 3 months.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All subjects must provide informed consent prior to initiation of any study activities.
All subjects must have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type and must have discontinued treatment and participation, including long-term follow-up (if applicable) in that trial.
You may not be if
Subjects currently receiving talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial.
Subject currently participating, including for long-term follow-up (if applicable), in other Amgen-sponsored talimogene laherparepvec clinical trial.
Clareo Health | Registry Study for Talimogene Laherparepvec
